Today’s Market Flows: BioShares Biotechnology Clinical Trials Fund Decreased by -25.99% Amid Negative Inflows. Registers $21.10M In Assets

Today's Market Flows: BioShares Biotechnology Clinical Trials Fund Decreased by  25.99% Amid Negative Inflows. Registers $21.10M In Assets

YTD BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) was a bottom performer after declining -25.99%. The ETF’s weekly performance is -0.48%. The ETF touched $21.10M assets under management. The chart of BioShares Biotechnology Clinical Trials Fund shows negative long-term setup. The stock decreased 2.77% or $0.52 on October 31, hitting $18.14. BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) has risen 1.97% since April 25, 2016 and is uptrending. It has underperformed by 4.04% the S&P500.

The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.

BioShares Biotechnology Clinical Trials Fund is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001.

More notable recent BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) news were published by: Etftrends.com which released: “Reasons to bet on new Breed Biotech ETFs” on April 17, 2015, also Nasdaq.com with their article: “The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P …” published on February 02, 2016, Seekingalpha.com published: “Bioshares New Equal Weight ETFs Offer Diversification And Growth” on December 22, 2014. More interesting news about BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) were released by: Etftrends.com and their article: “Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal” published on April 06, 2016 as well as Forbes.com‘s news article titled: “A More Viable Way To Invest In Top-Performing Biotech Stocks” with publication date: August 12, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment